Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee
Head of the Division of Biological Chemistry and Drug Discovery, Head of Chemistry in the Drug Discovery Unit, University of Dundee
Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological
Chemistry and Drug Discovery, University of Dundee, Dundee, DD1 5EH, United Kingdom
+44 1382 386 240
Ian Gilbert is Head of Chemistry in the Drug Discovery Unit (DDU). He is a medicinal chemist who has a focus on anti-infective drug discovery. Ian has had experience in leading a large variety of medicinal chemistry projects, including projects that have progressed to preclinical candidates. He is currently working on setting up an Antibacterial Drug Discovery Accelerator, with the aim of taking novel discoveries from microbiology laboratories and taking these into drug discovery projects to discover new chemotypes. This involves assay development, screening with small molecule libraries, optimization of the hits and then establishing mechanism of action of the hits. In addition to being Head of Chemistry in the DDU, Ian is also Head of the Division of Biological Chemistry and Drug Discovery and has 12 Principle Investigators and over 200 research scientists.
The Drug Discovery Unit (DDU) at the University of Dundee was founded in 2006. It has about 100 staff, focused on early phase drug discovery and works across multiple disease areas, but with a large proportion of work being anti-infective. The DDU has the capabilities to take projects from assay development through to preclinical candidate selection. The DDU has a selection of compound libraries (diverse, focused and fragment), robotics for compound handling & screening (both against proteins and cells), medicinal chemistry, computational chemistry, biophysical techniques (X-ray diffractometer, NMR spectrometer screening, SPR, biolayer interferometry, ITC), drug metabolism and pharmacokinetics. The DDU are highly experienced in anti-infective drug discovery and recently have delivered 3 preclinical candidates (malaria and visceral leishmaniasis). The DDU are in the process of setting up an Antibacterial Drug Discovery Accelerator with the aim of early phase drug discovery against bacteria, in particularly Gram-negative bacteria. Within Dundee is also a Division of Molecular Microbiology, who are collaborating with the DDU to carry out antibacterial drug discovery. In addition, there are interactions with the clinicians within the School of Medicine at Dundee.
Ian Gilbert will be responsible for interaction between the University of Dundee and the network. He will personally provide expertise in small molecule drug discovery. We will also look to form collaborations with other members of the Network as appropriate to progress particular drug discovery projects and validate new targets.